Navigation Links
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
Date:2/17/2013

ZURICH, February 18, 2013 /PRNewswire/ --

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a  recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients ages 18 years and older.

Piromelatine 20/50mg treatment for 4 weeks resulted in statistically significant and clinically meaningful improvements relative to placebo in key  polysomnographic (PSG) parameters including Wake After Sleep Onset (WASO) (p=0.02 for both doses) and in particular WASO for the first 6 hours of sleep (WASO-6h) (p=0.0008 and p=0.04 for the 50 mg and 20 mg groups, respectively). Piromelatine 50 mg also improved Sleep Efficiency (SEF) (p=0.02), Total Sleep Time (TST) (p=0.02), Total Time Awake (TTA) (p=0.01) and time in NREM sleep (p=0.028) indicating beneficial effects on sleep maintenance. Subjective improvements relative to placebo in quality of sleep and total sleep time measured by the Pittsburg Sleep Quality Questionnaire (PSQI) were also observed, confirming the PSG findings. Piromelatine enhanced NREM sleep EEG delta power and significantly reduced beta power (p<0.05). The decrease in EEG beta activity, a marker of cortical arousal, is a physiological surrogate marker of the efficacy of Piromelatine in sleep maintenance. Piromelatine was generally safe and well tolerated, had no detrimental effects on next-day psychomotor performance (as assessed by the Digit Symbol Substitution Test (DSST)) for any dose group and no deleterious effects on sleep structure and architecture.

"Piromelatine demonstrates a good potential for the treatm
'/>"/>

SOURCE Neurim Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... data at the American Association of Cancer ... on the potential for its lead product ...
(Date:5/29/2015)... 29, 2015 Educating the community continues ... for the Advancement of Wound Care (AAWC), which ... from AAWC,s corporate partners, the Association provides medical ... the AAWC website at http://aawconline.org/education-for-the-generalist/ . The ... with links to various CME/CEU educational programs. This ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... Reportlinker.com announces that a new market ... Germany Surgical Equipment Market ... http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment Germany Surgical Equipment ... Summary GlobalData,s new report, ...
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
Cached Medicine Technology:Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3
(Date:5/29/2015)... 2015 Dot Hill can mark one more item ... Lake Prince Woods retirement community is the oldest woman ... Virginia. , “It was great fun!”, she exclaimed. “I’ve always ... me to so they thought this would be ok.” , “We ... vertical wind tunnel,” she described. “I don’t remember it being ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 On May ... You Really be When You Get Botox ?” reported ... according to Google. Elle partnered with Google to determine these ... The most searched question in California, for example, is how ... the most common search query is what's the appropriate age ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Jan Wooden Howse ... in one thing above all else: God does no wrong. ... subject of her son’s passing is titled “God Does No ... is confronted with great personal tragedy. , “My story ... someone dear to you into something productive, something healing,” Howse ...
(Date:5/29/2015)... May 29, 2015 Johnson & ... a confidential Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement ... due to his use of the antipsychotic medication. ... selected for the third bellwether trial to involve ... litigation underway in Pennsylvania’s Philadelphia Court of Common ...
(Date:5/29/2015)... California (PRWEB) May 29, 2015 A group ... and have joined the national effort to teach this “new ... in the U.S. have been “sickened” by the recent implementation ... love it or hate it, Common Core is now a ... of Columbia. Parents are now seeking ways to improve ...
Breaking Medicine News(10 mins):Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Turning grief from a child’s passing into virtue 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2
... , , TEWKSBURY, Mass., ... is; on eggnog, cookies, candy and holiday buffet fare even though we ... the same with our four-legged, furry companions. The advent of the New ... for our pets, according to the experts at Wellness® Natural Food ...
... analyzing the genetics of cancers from different parts of the ... That process is already gaining traction at the ... where researchers are one year into a three-year project to ... gene expressed by 1,000 tumors. Over the past ...
... cellulose produced by bacteria could be used for artificial blood ... of blood clots than the synthetic materials currently used for ... the University of Gothenburg, Sweden. Produced by a bacterium ... enough to cope with blood pressure and works well with ...
... more serious infections than previously realised, with more than 3,000 ... Academy at the University of Gothenburg, Sweden. To date ... this often deadly infection is, but previously it has been ... in Sweden. A population-based review of cases in the county ...
... inherited form of disease , TUESDAY, Dec. 22 (HealthDay News) ... therapy may offer lifetime protection against the progression of the ... in mice. , The most common form of emphysema in ... in the alpha-1 anti-trypsin gene, the authors of the study ...
... , , ... ) today announced that its lending arm, IBM Global Financing, has ... (EHR) providers, highlighting the growing need for private financing for health ... adopt health IT solutions. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ) , ...
Cached Medicine News:Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 2Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 3Health News:Pets Resolve to 'Get Off On the Right Paw' in 2010 With a Healthy, Natural Diet and Exercise 4Health News:Chicago Cancer Genome Project studies genetics of 1,000 tumors 2Health News:Chicago Cancer Genome Project studies genetics of 1,000 tumors 3Health News:Chicago Cancer Genome Project studies genetics of 1,000 tumors 4Health News:Gene Therapy Holds Promise for Emphysema 2Health News:IBM Financing Agreements With Electronic Healthcare Record Providers Shatter Barriers To Health IT Adoption 2Health News:IBM Financing Agreements With Electronic Healthcare Record Providers Shatter Barriers To Health IT Adoption 3Health News:IBM Financing Agreements With Electronic Healthcare Record Providers Shatter Barriers To Health IT Adoption 4Health News:IBM Financing Agreements With Electronic Healthcare Record Providers Shatter Barriers To Health IT Adoption 5
PremierEdge Stab Knives - 15....
More Info Lacrimal Intubation Set. Size: Probes 23g x 7"....
... versatile and uncomplicated use of the Leica ... obtained make it the instrument of choice ... cryostat applications. The open top stainless steel ... accessible and offers ample space for convenient ...
The HM 550 series is a uniquely progressive concept for use with frozen specimens of all types. User applications define module selection and make even serial sectioning enjoyable....
Medicine Products: